Celgene Cellular Therapeutics (CCT) will perform testing of Homspera in order to evaluate the potential impact on cellular products in the company’s development pipeline. ImmuneRegen believes that Homspera will modify stem/progenitor cell activity which would be of value in multiple therapeutic applications of interest to both companies.
ImmuneRegen and Celgene have also agreed to explore other opportunities which may lead to complementary product development pipelines. Both the companies are exploring opportunities to jointly pursue US government funding in support of their rapid wound healing applications.